(Q42988539)

12 November 2017

title

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study (English)

1 reference

12 November 2017

1 reference

10

Kazuaki Chayama

1 reference

12 November 2017

14

Hiromitsu Kumada

1 reference

12 November 2017

13

Norio Akuta

1 reference

12 November 2017

12

Namiki Izumi

1 reference

12 November 2017

7

Eiji Tanaka

1 reference

12 November 2017

Takeshi Okanoue

1

1 reference

12 November 2017

Yoshito Itoh

2

1 reference

12 November 2017

Hiroaki Hashimoto

3

1 reference

12 November 2017

Kohichiroh Yasui

4

1 reference

12 November 2017

Masahito Minami

5

1 reference

12 November 2017

Tetsuo Takehara

6

1 reference

12 November 2017

Morikazu Onji

8

1 reference

12 November 2017

Joji Toyota

9

1 reference

12 November 2017

Kentaro Yoshioka

11

1 reference

12 November 2017

publication date

11 June 2009

1 reference

Journal of Gastroenterology

12 November 2017

published in

1 reference

12 November 2017

volume

44

1 reference

12 November 2017

issue

9

1 reference

12 November 2017

page(s)

952-963

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

12 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00535-009-0087-X

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

1 reference

12 December 2020

Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.

1 reference

12 December 2020

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

12 December 2020

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

12 December 2020

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

1 reference

12 December 2020

Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC).

1 reference

12 December 2020

A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase

1 reference

12 December 2020

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

1 reference

12 December 2020

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

12 December 2020

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

1 reference

12 December 2020

Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads

1 reference

12 December 2020

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

1 reference

12 December 2020

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors

1 reference

12 December 2020

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

1 reference

12 December 2020

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

12 December 2020

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

12 December 2020

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

1 reference

12 December 2020

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

1 reference

12 December 2020

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

12 December 2020

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

1 reference

12 December 2020

Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts

1 reference

12 December 2020

A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase

1 reference

12 December 2020

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

1 reference

12 December 2020

Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group

1 reference

12 December 2020

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).

1 reference

12 December 2020

Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C.

1 reference

12 December 2020

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

12 December 2020

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

12 December 2020

High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy

1 reference

12 December 2020

Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy

1 reference

12 December 2020

10.1007/S00535-009-0087-X

Identifiers

DOI

1 reference

12 November 2017

1 reference